Sana Biotechnology, Inc. financial data

Symbol
SANA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
188 East Blaine Street, Suite 400, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 389 % -8.28%
Debt-to-equity 86.9 % +41.9%
Return On Equity -89.2 % -48.6%
Return On Assets -47.8 % -28.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 222M shares +15.8%
Common Stock, Shares, Outstanding 221M shares +15.6%
Entity Public Float 600M USD -50%
Common Stock, Value, Issued 22K USD +15.8%
Weighted Average Number of Shares Outstanding, Basic 217M shares +13.6%
Weighted Average Number of Shares Outstanding, Diluted 217M shares +13.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 258M USD -7.94%
General and Administrative Expense 72.8M USD -1.48%
Operating Income (Loss) -320M USD +1.58%
Net Income (Loss) Attributable to Parent -309M USD +3.61%
Earnings Per Share, Basic -1.52 USD/shares +10.1%
Earnings Per Share, Diluted -1.52 USD/shares +10.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 177M USD +10.3%
Marketable Securities, Current 134M USD -29%
Assets, Current 321M USD -13.2%
Property, Plant and Equipment, Net 81.6M USD +27.1%
Operating Lease, Right-of-Use Asset 71.6M USD -27.1%
Intangible Assets, Net (Excluding Goodwill) 59.2M USD 0%
Goodwill 141M USD 0%
Other Assets, Noncurrent 7.08M USD +54.2%
Assets 681M USD -8.78%
Accounts Payable, Current 6.1M USD +161%
Employee-related Liabilities, Current 14M USD -18%
Liabilities, Current 52.9M USD -48.5%
Operating Lease, Liability, Noncurrent 92.9M USD -8.55%
Liabilities 306M USD -3.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -15K USD +99.3%
Retained Earnings (Accumulated Deficit) -1.45B USD -27.1%
Stockholders' Equity Attributable to Parent 375M USD -12.4%
Liabilities and Equity 681M USD -8.78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -65.6M USD +17.2%
Net Cash Provided by (Used in) Financing Activities 186M USD +78882%
Net Cash Provided by (Used in) Investing Activities -77.2M USD -223%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 221M shares +15.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 43.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 181M USD +5.8%
Deferred Tax Assets, Valuation Allowance 403M USD +46.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 425M USD +42.2%
Operating Lease, Liability 106M USD -7.35%
Depreciation 24M USD +47.4%
Payments to Acquire Property, Plant, and Equipment 15.8M USD +628%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -306M USD +3.35%
Lessee, Operating Lease, Liability, to be Paid 193M USD -20.2%
Property, Plant and Equipment, Gross 127M USD +24%
Operating Lease, Liability, Current 13.2M USD +2.13%
Lessee, Operating Lease, Liability, to be Paid, Year Two 22.5M USD -20.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 25.4M USD -9.38%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 86M USD -19.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 19.9M USD -21.2%
Deferred Tax Assets, Operating Loss Carryforwards 192M USD +24.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15.2M USD -33.2%
Additional Paid in Capital 1.82B USD +16.2%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 0 USD
Deferred Tax Assets, Net of Valuation Allowance 22.5M USD -9.02%
Share-based Payment Arrangement, Expense 35.9M USD -8.79%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%